Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaxMist ENT
- Development stage
- Preclinical
- Lead developer
- Bennett Pharmaceuticals of America
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
MaxMist ENT is a needle-free intranasal anesthetic spray developed by Bennett Pharmaceuticals for use in ear, nose, and throat (ENT) procedures. It is designed to provide localized anesthesia to the nasal mucosa, offering a non-invasive alternative to traditional needle-based injections. By delivering anesthetic agents via a spray formulation, the product aims to reduce patient anxiety and discomfort while improving procedural efficiency during minor ENT interventions and examinations.
- Brand names
- MaxMist ENT
02
Targets
ADRA1A (α1A)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on MaxMist ENT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxMist ENT.